Xtant Medical Hldgs Stock Price To Earnings To Growth
| XMS Stock | EUR 0.34 0.01 3.03% |
XTANT MEDICAL HLDGS fundamentals help investors to digest information that contributes to XTANT MEDICAL's financial success or failures. It also enables traders to predict the movement of XTANT Stock. The fundamental analysis module provides a way to measure XTANT MEDICAL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTANT MEDICAL stock.
XTANT |
XTANT MEDICAL HLDGS Company Price To Earnings To Growth Analysis
XTANT MEDICAL's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, XTANT MEDICAL HLDGS has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The price to earnings to growth for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run AI Portfolio Architect Now
AI Portfolio ArchitectUse AI to generate optimal portfolios and find profitable investment opportunities |
| All Next | Launch Module |
XTANT Fundamentals
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0619 | |||
| Profit Margin | (0.15) % | |||
| Operating Margin | (0.1) % | |||
| Shares Outstanding | 108.66 M | |||
| Shares Owned By Insiders | 7.59 % | |||
| Shares Owned By Institutions | 75.17 % | |||
| Revenue | 56.67 M | |||
| Gross Profit | 32.49 M | |||
| EBITDA | (4.28 M) | |||
| Net Income | (2.83 M) | |||
| Cash And Equivalents | 20.31 M | |||
| Cash Per Share | 0.23 X | |||
| Total Debt | 17.43 M | |||
| Debt To Equity | 0.51 % | |||
| Current Ratio | 3.83 X | |||
| Book Value Per Share | 0.32 X | |||
| Cash Flow From Operations | 1.79 M | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 116 | |||
| Beta | 0.63 | |||
| Market Capitalization | 72.54 M | |||
| Z Score | 2.4 |
About XTANT MEDICAL Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTANT MEDICAL HLDGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTANT MEDICAL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTANT MEDICAL HLDGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in XTANT Stock
XTANT MEDICAL financial ratios help investors to determine whether XTANT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTANT with respect to the benefits of owning XTANT MEDICAL security.